HMGB1 and inflammatory bowel disease: The beneficial effects of EP in animal models of T1D [13], rheumatoid arthritis [23], systemic lupus erythematosus [14], autoimmune orchitis [11], and inflammatory bowel disease [24,25] were also associated with HMGB1 inhibition in the tissues targeted by the pathogenesis.